[Correction Notice: An erratum for this article was reported in Vol 22(8) of Journal of Psychopharmacology (see record 2008-16669-018). Journal of Psychopharmacology published an Editorial by the authors to which there was a reply from Green Marsden and Fone, published online, entitled ‘MDMA as a clinical tool: a note of caution. A response to Sessa and Nutt’ followed by a reply from the authors which was published in the June issue. The Editorial office regret that the reply from Green, et al. had not been published in print before the reply form Sessa and Nutt. We would like to apologize for any confusion or difficulties this may have caused.] 3,4-Methylenedioxymethlyamphetamine (MDMA) has penetrated extensively into our culture in the last thirty years. It started life in medicine when adopted as a clinical tool by psychotherapists on the West Coast of America who used it as an alternative to the then banned LSD for facilitating interactions in couples' therapy. The development of MDMA as a tool to assist psychotherapy is now well underway, but perhaps, the next stage of exploring the drug's potential lies in proposing a study that investigates it's role as a potent serotonin agonist to rapidly elevate mood. However, a study such as this remains extremely difficult to put forward given the continuing prohibition. Should such studies prove successful they could offer a novel approach to the treatment of depression although the current laws mitigate against pharma following up such findings with new drugs with the same actions. This situation is bad for science and bad for patients and quite illogical. We must not let MDMA research be hijacked by politics, as has happened with LSD. MDMA is a medical tool and it deserves to remain within medicine. (PsycINFO Database Record (c) 2012 APA, all rights reserved)